Mordin M, Parrish W, Masaquel C, Bisson B, Copley-Merriman K. Intra-articular hyaluronic acid for osteoarthritis of the knee in the United States: a systematic review of economic evaluations. Clin Med Insights Arthritis Musculoskelet Disord. 2021 Nov 19;14:1-13. doi: 10.1177/11795441211047284
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Alseda P, Castan MT, Barbe F. Mental disorders in chronic obstructive pulmonary diseases. Perspect Psychiatr Care. 2018 Jul;54(3):398-404. doi: 10.1111/ppc.12274
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Pinto MD, Greenblatt AM, Hickman RL, Rice HM, Thomas TL, Clochesy JM. Assessing the critical parameters of eSMART-MH: a promising avatar-based digital therapeutic intervention to reduce depressive symptoms. Perspect Psychiatr Care. 2016 Jul;52(3):157-68. doi: 10.1111/ppc.12112
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.